Advertise on podcast: New Retina Radio by Eyetube

Does phacovitrectomy improve outcomes over conventional PPV for rhegmatogenous retinal detachment repair in a phakic eyes? Or does it introduce unnecessary complexity? Vaidehi Dedania, MD; Yewlin Chee, MD; and Joshua Uhr, MD, review results from a multicenter cohort study published in Ophthalmology Retina and discuss whether the study's findings have any bearing on real-world decision-making, parse generational differences regarding perceived phacovitrectomy risks, and review whether changes to technology during the course of the study may have affected the findings.

Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Matthew Starr, MD, a vitreoretinal surgeon at the Mayo Clinic, and Timothy Xu, MD, a retina fellow at Wills Eye Hospital, to discuss retained lens fragments and secondary IOLs. They share complex cases, when to consider following patients medically, surgical techniques for removing fragments, and how to make the best secondary lens choice.

In this episode of RetinaLive focused on UNITY® VCS|CS, Matt Cunningham, MD, FASRS, welcomes Steven Yeh, MD, FASRS for a reflection on early clinical experience with the UNITY® VCS system following the first 50 cases. The discussion highlights real-world insights on surgical efficiency, fluidics stability, and intraoperative control across a range of case complexities. From seamless OR integration to advancements in 27-gauge instrumentation and laser delivery, the conversation offers practical perspectives on adoption, training, and how evolving technology can enhance surgeon confidence and patient care. For Important Product Information, visit unityvcs.com. Speakers are paid Alcon consultants. The views expressed are their own. Disclaimers: 3:58: For posterior segment surgeries/posterior cassette pack § ~1.7 minutes faster. 4:30: For posterior segment surgeries/posterior cassette pack § ~1.7 minutes faster. 10:49: Versus Alcon's Non-Dynamic Stiffener 27+ technology 11:09: Versus Alcon's Non-Dynamic Stiffener 27+ technology 11:17: Versus Alcon's Non-Dynamic Stiffener 27+ technology 11:46: Versus Alcon's Non-Dynamic Stiffener 27+ technology 11:58: MSLP(4) is 3 times faster than SSLP 12:15: MSLP(4) is 3 times faster than SSLP 12:26: MSLP(4) is 3 times faster than SSLP 13:18: Versus Alcon's Non-Dynamic Stiffener 27+ technology 13:39: Versus Alcon's Non-Dynamic Stiffener 27+ technology 17:30: Versus Alcon's Non-Dynamic Stiffener 27+ technology 18:25: For posterior segment surgeries/posterior cassette pack ~1.7 minutes faster. References: 1. Alcon Data on File, 2025. (REF-28170) 2. UNITY™ VCS and CS User Manual 3. Vasavada V, Agrawal D, Vasavada SA, Vasavada AR, Yagnik J. Intraoperative performance and early postoperative outcomes following phacoemulsification with three fluidic systems: A randomized trial. J Refract Surg. 2024;40(5):e304-e312. 4. Sugiura Y, Okamoto F, Okamoto Y, Hiraoka T, Oshika T. Intraocular pressure fluctuations during microincision vitrectomy with Constellation Vision System. Am J Ophthalmol. 2013;156(5)941-947 5. Alcon data on file 2024. (REF-24576) 6. Alcon data on file 2024 (REF-24615) 7. Alcon data on file 2024 (REF-24379) 9. Alcon data on file 2024 (REF-24644) 10. Alcon data on file 2024. (REF-24615) 11. UNITY™ VCS and CS User Manual Unity Phaco Handpiece Directions for Use. Sponsored by Alcon, Inc. © 2026 Alcon Inc. 07/26 US-UVC-2600114

How aggressively should you manage a vitreous hemorrhage after a PVD when you can't see the retina underneath it? Barton Blackorby, MD, moderates a discussion with Matt Starr, MD, and Kyle Kovacs, MD, about a study published in Ophthalmology by Hasbolat et al examining 366 patients with PVD-related vitreous hemorrhage initially managed with observation. The panel discusses how exam technique and B-scan reliance may affect detachment detection rates, debates follow-up intervals given that most retinal detachments in the study occurred within the first 3 weeks, and shares their own thresholds for moving to early vitrectomy versus continued observation, including how they counsel patients eager for faster visual recovery.

In this episode of RetinaLive focused on UNITY® VCS|CS, Jay Sridhar, MD is joined by Nina Berrocal, MD for a forward-looking discussion on adopting next-generation surgical technology. The conversation explores how UNITY® VCS is enabling innovation in a new retina practice setting, with a focus on fluidics stability, integrated anterior and posterior segment capabilities, and enhanced intraoperative efficiency. Through real-world perspectives, the episode highlights the role of advanced technology in simplifying surgical workflows, and supporting the training of the next generation of retina surgeons. For Important Product Information, visit unityvcs.com. Speakers are paid Alcon consultants. The views expressed are their own. Disclaimers: 4:05: Based on Bench Data. UNITY® VCS with HYPERVIT® 30k cpm vitrectomy probe vs. CONSTELLATION® VS with HYPERVIT® 20k cpm vitrectomy probe 6:13: *Mean fluctuation at flow vs. setpoint of 2.36 ± 2.13, 4.19 ± 1.97, 1.84 ± 2.82, and 2.13 ± 2.86 mmHg during phacoemulsification, irrigation/aspiration (IA), vitrectomy, and extrusion/fragmentation, respectively. IOP setpoint as low as 16 mmHg (posterior) and 20 mmHg (anterior) without exceeding a mean fluctuation of 4.19 ± 1.97 mmHg 9:08: MSLP(4) is 3 times faster than SSLP References: 1. UNITY™ VCS and CS User Manual Unity Phaco Handpiece Directions for Use.  2. Alcon data on file 2024 (REF-24615) 3. Alcon data on file 2024 (REF-24379) 4. Alcon data on file 2024 (REF-24576) 5. Alcon Data on File (REF-27800) 6. UNITY™ VCS and CS User Manual 7. Alcon data on file 2024. (REF-24899)   Sponsored by Alcon, Inc. © 2026 Alcon Inc. 07/26 US-UVC-2600112

Can a single molecule treat both GA and Stargardt Disease? And if so, how far along is the research? Jay Chhablani, MD, joins New Retina Radio to share data from ArMaDa and GARDian, which assessed OCU410 (Ocugen) in geographic atrophy and Stargardt disease, respectively. And Jordan Deaner, MD, sits down to discuss his research on real-world retinal tears and detachments following YAG capsulotomy. What are the actual incidence rates? And what risk factors were identified? Stick with us to find out.

What can pharmacovigilance data tell us about the post-marketing safety profiles of anti-VEGF agents, and where do those signals fall short? In this episode of New Retina Radio Journal Club with VBS, Katherine Talcott, MD, moderates a discussion with Akshay Thomas, MD, and Nita Valikodath, MD, MS, on a 2026 study comparing ocular adverse event reporting for aflibercept 2 mg (Eylea, Regeneron), aflibercept 8 mg (Eylea HD, Regeneron), and faricimab (Vabysmo, Genentech/Roche) using the FDA Adverse Event Reporting System. The group examines distinct signal profiles for each agent and makes the case for why these findings should be viewed as hypothesis-generating rather than evidence of causality.

In this episode of New Retina Radio, host Barry Kuppermann, MD, PhD, sits down with Bob Jahr, CEO of Outlook Therapeutics, to discuss the FDA approval of LYTENAVA™ (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab formulation for nAMD.1,2 They explore the regulatory journey over the course of more than 8 years,3 the rigorous FDA review process,4 manufacturing and product quality, commercialization plans, payer considerations, and future development. Please see the Important Safety Information and full US Prescribing Information for LYTENAVA. Intended for a US audience only. Sponsored by Outlook Therapeutics References 1. Harp MD. FDA approves Outlook Therapeutics' LYTENAVA for the treatment of wet AMD. Ophthalmology Times. Published July 24, 2026. Accessed July 28, 2026. https://www.ophthalmologytimes.com/view/fda-approves-outlook-therapeutics-lytenava-for-the-treatment-of-wet-amd 2. LYTENAVA™ (bevacizumab-vikg) prescribing information. Outlook Therapeutics; 2026. 3. Outlook Therapeutics. Oncobiologics changes name to Outlook Therapeutics; announces next steps in executing ONS-5010 clinical and regulatory strategy. Published December 3, 2018. Accessed July 24, 2026. https://ir.outlooktherapeutics.com/news-releases/news-release-details/oncobiologics-changes-name-outlook-therapeutics-announces-next 4. US Food and Drug Administration. The FDA's drug review process: ensuring drugs are safe and effective. Updated January 4, 2018. Accessed July 28, 2026. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective

Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Monia Reding, MD, a retina fellow at Casey Eye Institute, and Benjamin Young, MD, assistant professor of Ophthalmology at Casey Eye Institute, to talk about lasers. They share the pros and cons of slit-lamp laser and indirect, ergonomics, laser settings, difficult scenarios, and the personal experiences that shape their practice patterns.

Could TKIs be the game-changing therapy that makes wet AMD treatment less burdensome? Dilsher Dhoot, MD, joins the show to examine the SOL-1 study, a superiority study assessing the safety, efficacy, and durability of axitinib (Axpaxli, Ocular Therapeutix) for the treatment of wet AMD. And Carl Danzig, MD, stops by to deliver the 4.5-year data from TRUCKEE, which tells us how real-world patients with wet AMD perform when dosed with faricimab (Vabysmo, Genentech/Roche). How are patients doing after 3, 6, or even 9 doses? Stick with us to find out.

What do large registry data reveal about outcomes after intraocular foreign body removal, and how should those findings shape surgical planning and patient counseling? In this episode of New Retina Radio Journal Club with VBS, Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, on a 2025 IRIS Registry analysis of nearly 4,800 eyes. The group reviews the delayed timeline of visual recovery, the risk of late complications, and practical guidance on staging surgical intervention and setting realistic expectations in complex trauma cases.

What stands between a patient with geographic atrophy and consistent, effective treatment? And how do clinicians bridge that gap? In episode 3 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, address injection burden, insurance hurdles, and the role of patient education tools in supporting adherence. The group also weighs the potential for AI to guide treatment decisions and track progression, then works through a hypothetical case of an 82-year-old caregiver with bilateral diffuse trickling GA who is not yet motivated to pursue treatment.

How have 3 years of real-world experience with complement inhibition changed when and how retina specialists treat GA? In episode 2 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, examine how referral patterns, safety data, and extension study findings have shifted their approach to early treatment. The group then works through a hypothetical case of an active 73-year-old patient with extrafoveal GA and intermediate AMD in the fellow eye, exploring how lesion characteristics, CNV risk counseling, and months-long travel schedules factor into the treatment decision.

Which imaging biomarkers matter most at diagnosis of GA, and how should they shape the decision to treat? In episode 1 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, review the practical role of fundus autofluorescence and OCT in identifying high-risk GA, discuss ellipsoid zone integrity as an emerging endpoint, and work through a hypothetical case of an active, motivated patient with bilateral extrafoveal GA and good vision to explore how lifestyle, lesion characteristics, and patient education factor into early treatment decisions.

Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Omesh P. Gupta, MD, retina specialist at Wills Eye Hospital, and Shane Griffin, MD, MCR, vitreoretinal surgery fellow at the University of California San Diego Shiley Eye Institute, to discuss scleral-fixating secondary IOLs. They share pearls for implantation success, advanced techniques, and tricks for handling complicated cases.